GlassScriptPhysician profile
John R Holman
NPI 1215938394
$2,631.07
in general payments reported to CMS, 2019-2025
33 companies · $648 in 2025
The $648 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $508 · 2021: $662 · 2022: $37.10 · 2023: $20.45 · 2024: $146 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $449.34 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $268.95 | 2019-2025 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $245.45 | 2019-2021 | |
| Glaxosmithkline, LLC. | $216.59 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $157.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $128.74 | 2019-2025 | |
| Allergan, INC. | $107.41 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $102.21 | 2019-2021 | |
| Organogenesis INC. | $85.17 | 2019-2021 | |
| Lilly USA, LLC | $69.39 | 2020-2021 | |
| Amgen INC. | $66.51 | 2020-2024 | Krystexxa |
| Edwards Lifesciences Corporation | $58.93 | 2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $51.62 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $50.35 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $41.72 | 2020-2021 | |
| Esperion Therapeutics, INC. | $39.91 | 2020-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.17 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $36.49 | 2021 | |
| Aimmune Therapeutics, INC. | $32.95 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.70 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $28.51 | 2025 | |
| Zyla Life Sciences, INC. | $25.09 | 2020 | |
| Mayne Pharma Commercial LLC | $22.64 | 2025 | |
| Therapeuticsmd, INC. | $20.96 | 2019 | |
| Eisai INC. | $20.56 | 2021 | |
| Astellas Pharma US INC | $19.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.43 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.43 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.98 | 2020 | |
| Novo Nordisk INC | $13.55 | 2020 | |
| Nevro Corp. | $12.77 | 2019 | |
| Amarin Pharma, INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Holman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.